Daiichi Sankyo Company, Limited

4568.T
Drug Manufacturers - General
2026/03/02 Updated
Market Cap: $36.3B (¥5.7T)
Stock Price: $19.64 (¥3,064)
Exchange Rate: 1 USD = ¥156.01

Notification Regarding Changes to Representative Director and Selection of Director and Auditor Candidates

Change of representative director effective June 22, 2026. Mr. Takashi Matsumoto is scheduled to assume the new representative director role. Selection of director and auditor candidates has also been conducted to enhance diversity and expertise.

Importance:
Page Updated: February 26, 2026
IR Disclosure Date: February 26, 2026

Key Figures

  • New Representative Director Assumption Date: 2026年6月22日
  • Outgoing Representative Director Chairman: Mr. Jun Manabe (effective June 22, 2026)
  • New Auditor Candidates: Mr. Takashi Murata, Ms. Sayuri Tago (effective June 22, 2026)

AI要約

Regarding the Change of Representative Director

Daiichi Sankyo Company, Limited will implement a change of representative director following the conclusion of the 21st Annual General Meeting of Shareholders scheduled for June 22, 2026, upon expiration of the term of office. The candidates for new representative directors have been selected as Mr. Takashi Matsumoto (current Senior Executive Officer, CHRO) and Ms. Tsuzuko Ueno (current Executive Officer, Head of Japan Business Unit). Meanwhile, Mr. Jun Manabe is scheduled to retire as Representative Director Chairman and assume the position of a full-time advisor.

Selection of Director and Auditor Candidates

Director candidates include the incumbent President and CEO Mr. Hiroyuki Okuzawa, Mr. Takashi Matsumoto, Ms. Tsuzuko Ueno, and Mr. Joseph Kenneth Keller, who will be reappointed or newly appointed. Mr. Stuart Mackie has been selected as a new director. Auditor candidates slated for new appointment include Mr. Takashi Murata, former Cabinet Crisis Management Director, and Ms. Sayuri Tago, an attorney. These appointments aim to strengthen the board’s diversity and expertise.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.